Ofatumumab and rituximab: reactivation of HBV infection United States of America — The Food and Drug Administration (FDA) has approved changes to the prescribing information for ofatumumab (Arzerra®) and rituximab (Rituxan®) to warn of the risk of reactivation of hepatitis B virus (HBV) infection. The revised labelling will also include additional recommendations for screening, monitoring and managing patients. Both ofatumumab and rituximab are used to treat certain cancers of the blood and lymph system. Rituximab is also approved to treat other medical conditions, including rheumatoid arthritis. Both drugs suppress the immune system.
In patients with prior HBV infection, HBV reactivation may occur when the body’s immune system is impaired. Infection can cause serious liver problems, including liver failure and death. The risk of HBV reactivation is already described in the labelling for both drugs; however, cases continue to occur, including deaths. Reference: FDA Drug Safety Communication, 25 August 2013 at
http://www.fda.gov/Drugs/ DrugSafety/ucm366406.htm
Ofatumumab and rituximab抑制免疫药物重新激活HBV
原文：http://www.cnblogs.com/biopy/p/5213444.html